Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational challenges.</li><li>The company posted a 7% increase in reported revenue in the fourth quarter and 9% growth for the full year, with constant currency organic revenue growth at 5% for the quarter and 7% for the year.</li><li>Growth was driven primarily by volume increases and pricing gains, with approximately 230 basis points of price benefit in Q4.</li></ul>

STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational challenges.The company posted a 7% increase in reported revenue in the fourth quarter and 9% growth for the full year, with constant currency organic revenue growth at 5% for the quarter and 7% for the year.Growth was driven primarily by volume increases and pricing gains, with approximately 230 basis points of price benefit in Q4.

STERIS’ $400 Million Healthcare Backlog Puts Equipment Demand Back In Focus!

<ul><li>STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges.</li><li>The company's revenue increased by 9% year-over-year, with constant currency organic revenue growth at 8%.</li><li>This growth was fueled by volume increases and a favorable pricing environment that contributed 200 basis points to revenue growth.</li></ul>

STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges.The company's revenue increased by 9% year-over-year, with constant currency organic revenue growth at 8%.This growth was fueled by volume increases and a favorable pricing environment that contributed 200 basis points to revenue growth.

STERIS: Is Its Aggressive EMEA Push the Hidden Catalyst Investors Are Overlooking?

<ul><li>STERIS plc recently reported its second-quarter fiscal 2026 results, revealing a strong performance marked by a 10% increase in total as-reported revenue and a 9% rise in constant currency organic revenue, driven by volume growth and favorable pricing.</li><li>Gross margin improved by 60 basis points to 44.3%, as higher productivity and pricing offset inflation and tariff impacts.</li><li>Earnings before interest and taxes (EBIT) margin also saw a notable increase of 90 basis points to 23.1%.</li></ul>

STERIS plc recently reported its second-quarter fiscal 2026 results, revealing a strong performance marked by a 10% increase in total as-reported revenue and a 9% rise in constant currency organic revenue, driven by volume growth and favorable pricing.Gross margin improved by 60 basis points to 44.3%, as higher productivity and pricing offset inflation and tariff impacts.Earnings before interest and taxes (EBIT) margin also saw a notable increase of 90 basis points to 23.1%.

STERIS: How Repair-and-Maintenance Bundles Are Quietly Becoming Its Most Reliable Growth Lever!

<ul><li>STERIS plc's first quarter of fiscal 2026 demonstrates a solid start to the financial year, with several key performance metrics showcasing both growth and resilience amidst challenging macroeconomic conditions.</li><li>The company reported a 9% increase in total revenue, and an 8% rise in constant currency organic revenue growth, pointing to robust operational performance that was primarily driven by volume and a favorable pricing environment.</li><li>This growth in revenue was accompanied by a slight increase in gross margin, up 20 basis points from the previous year to 45.3%.</li></ul>

STERIS plc's first quarter of fiscal 2026 demonstrates a solid start to the financial year, with several key performance metrics showcasing both growth and resilience amidst challenging macroeconomic conditions.The company reported a 9% increase in total revenue, and an 8% rise in constant currency organic revenue growth, pointing to robust operational performance that was primarily driven by volume and a favorable pricing environment.This growth in revenue was accompanied by a slight increase in gross margin, up 20 basis points from the previous year to 45.3%.

STERIS plc: Initiation of Coverage- These Are The 6 Biggest Factors Impacting Its Performance In 2025 & Beyond!

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).</li>
<li>Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold</li>
<li>The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS</li>
</ul>


We downgraded our near-term outlook on SPX and QQQ to neutral last week (11/19/25), after being bullish since 4/22/25, while we maintained our intermediate-term bullish outlook (as of 5/14/25).
Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are back to being near-term bullish as long as these supports continue to hold
The latest pullback offers an attractive entry point into all the speculative growth areas that we were pounding the table on since May, WITH A STOP AT LAST WEEKS LOWS


Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

United States

STERIS Public Limited Company operates as a provider of infection prevention and other procedural products and services. The Company offers sterilizers and washers, surgical tables, lights and equipment management systems, and endoscopy accessories. STERIS serves healthcare, pharmaceutical, and medical device industries.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

STERIS (STE US)

STERIS’ $400 Million Healthcare Backlog Puts Equipment Demand Back In Focus!

STERIS plc reported financial results for fiscal year 2026 reflecting a mixed but overall steady performance amid ongoing economic and operational...

Baptista Research

STERIS: Is Its Aggressive EMEA Push the Hidden Catalyst Investors Are Overlooking?

STERIS plc reported its third-quarter results for fiscal year 2026, highlighting both growth and challenges. The company's revenue increased by 9%...

Baptista Research

STERIS: How Repair-and-Maintenance Bundles Are Quietly Becoming Its Most Reliable Growth Lever!

STERIS plc recently reported its second-quarter fiscal 2026 results, revealing a strong performance marked by a 10% increase in total as-reported...

Baptista Research

STERIS plc: Initiation of Coverage- These Are The 6 Biggest Factors Impacting Its Performance In 2025 & Beyond!

STERIS plc's first quarter of fiscal 2026 demonstrates a solid start to the financial year, with several key performance metrics showcasing both...

Baptista Research

Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583

Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)